Literature DB >> 21312096

[Reirradiation of recurrent glioblastoma].

Dietmar Seewald1.   

Abstract

Patients with glioblastoma are treated by radiotherapy in combination with temozolamid. Recurrent and progressive disease can be managed by several treatment options. Some series reported about reirradiation of brain tumors, but there are no randomised studies. Modern high precise radiation techniques can be an option for a save and effective treatment without systemic side effects. The published series show median survival rates from 6 to 12 months. Concomitant systemic therapies are evaluated in phase I/II studies. Indication for irradiation and decision of the technique and fractionation scheme have to be chosen individually. There is no curative intent for reirradiation, possible serious side effects and negative influence on life quality have to be omitted.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21312096     DOI: 10.1007/s10354-010-0862-6

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  10 in total

1.  Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM).

Authors:  Stephanie E Combs; Verena Widmer; Christoph Thilmann; Holger Hof; Juergen Debus; Daniela Schulz-Ertner
Journal:  Cancer       Date:  2005-11-15       Impact factor: 6.860

2.  Reirradiation of primary brain tumours: survival, clinical response and prognostic factors.

Authors:  T Veninga; H A Langendijk; B J Slotman; E H Rutten; A J van der Kogel; M J Prick; A Keyser; R W van der Maazen
Journal:  Radiother Oncol       Date:  2001-05       Impact factor: 6.280

3.  Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas.

Authors:  K H Cho; W A Hall; B J Gerbi; P D Higgins; W A McGuire; H B Clark
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-12-01       Impact factor: 7.038

4.  Reirradiation of primary CNS tumors.

Authors:  G S Bauman; P K Sneed; W M Wara; L J Stalpers; S M Chang; M W McDermott; P H Gutin; D A Larson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-09-01       Impact factor: 7.038

5.  Hypofractionated stereotactic radiotherapy in the management of recurrent glioma.

Authors:  S F Shepherd; R W Laing; V P Cosgrove; A P Warrington; F Hines; S E Ashley; M Brada
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-01-15       Impact factor: 7.038

6.  Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.

Authors:  Anca L Grosu; Wolfgang A Weber; Martina Franz; Sibylle Stärk; Morand Piert; Reinhard Thamm; Hartmut Gumprecht; Markus Schwaiger; Michael Molls; Carsten Nieder
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-01       Impact factor: 7.038

7.  Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution.

Authors:  Stephanie E Combs; Christoph Thilmann; Lutz Edler; Jürgen Debus; Daniela Schulz-Ertner
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

Review 8.  Reirradiation tolerance of the human brain.

Authors:  Ramona Mayer; Peter Sminia
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-26       Impact factor: 7.038

9.  Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.

Authors:  Philip H Gutin; Fabio M Iwamoto; Kathryn Beal; Nimish A Mohile; Sasan Karimi; Bob L Hou; Stella Lymberis; Yoshiya Yamada; Jenghwa Chang; Lauren E Abrey
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-01-23       Impact factor: 7.038

10.  Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma.

Authors:  Dirk Vordermark; Oliver Kölbl; Klemens Ruprecht; Giles H Vince; Klaus Bratengeier; Michael Flentje
Journal:  BMC Cancer       Date:  2005-05-30       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.